JP2018203681A - くせ毛改善剤 - Google Patents
くせ毛改善剤 Download PDFInfo
- Publication number
- JP2018203681A JP2018203681A JP2017112250A JP2017112250A JP2018203681A JP 2018203681 A JP2018203681 A JP 2018203681A JP 2017112250 A JP2017112250 A JP 2017112250A JP 2017112250 A JP2017112250 A JP 2017112250A JP 2018203681 A JP2018203681 A JP 2018203681A
- Authority
- JP
- Japan
- Prior art keywords
- hair
- ascorbic acid
- collagen
- hair follicle
- vicious
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004209 hair Anatomy 0.000 title claims abstract description 83
- 230000006872 improvement Effects 0.000 title abstract description 15
- 210000003780 hair follicle Anatomy 0.000 claims abstract description 49
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 27
- 150000000996 L-ascorbic acids Chemical class 0.000 claims abstract description 22
- 230000037319 collagen production Effects 0.000 claims abstract description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 31
- 239000002211 L-ascorbic acid Substances 0.000 claims description 18
- 229960005070 ascorbic acid Drugs 0.000 claims description 18
- 235000000069 L-ascorbic acid Nutrition 0.000 claims description 16
- 108010035532 Collagen Proteins 0.000 abstract description 33
- 102000008186 Collagen Human genes 0.000 abstract description 31
- 229920001436 collagen Polymers 0.000 abstract description 30
- 210000004207 dermis Anatomy 0.000 abstract description 21
- 238000004519 manufacturing process Methods 0.000 abstract description 15
- 239000003814 drug Substances 0.000 abstract description 7
- 239000002537 cosmetic Substances 0.000 abstract description 6
- 210000002615 epidermis Anatomy 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 5
- 230000032683 aging Effects 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 230000007246 mechanism Effects 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 abstract description 2
- 230000001133 acceleration Effects 0.000 abstract 4
- 230000008878 coupling Effects 0.000 abstract 1
- 238000010168 coupling process Methods 0.000 abstract 1
- 238000005859 coupling reaction Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 25
- 238000009472 formulation Methods 0.000 description 22
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 210000004761 scalp Anatomy 0.000 description 8
- -1 L- ascorbic acid 2-glucoside L- ascorbic acid glycosides Chemical class 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- 230000001256 tonic effect Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 210000004919 hair shaft Anatomy 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 239000002304 perfume Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 210000001208 inner root sheath cell Anatomy 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 210000002469 basement membrane Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 210000004918 root sheath Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000004873 anchoring Methods 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000000720 eyelash Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000031774 hair cycle Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 229940119170 jojoba wax Drugs 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000012014 optical coherence tomography Methods 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- DBSABEYSGXPBTA-RXSVEWSESA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O DBSABEYSGXPBTA-RXSVEWSESA-N 0.000 description 1
- CGFPNELNAZZYQL-RXSVEWSESA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;sulfuric acid Chemical compound OS(O)(=O)=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CGFPNELNAZZYQL-RXSVEWSESA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- QAQJMLQRFWZOBN-UHFFFAOYSA-N 2-(3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl)-2-hydroxyethyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)C1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102100024203 Collagen alpha-1(XIV) chain Human genes 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000909626 Homo sapiens Collagen alpha-1(XIV) chain Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 102000004371 Insulin-like growth factor binding protein 5 Human genes 0.000 description 1
- 108090000961 Insulin-like growth factor binding protein 5 Proteins 0.000 description 1
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 1
- XDBMXUKHMOFBPJ-ZAFYKAAXSA-N L-ascorbic acid 2-sulfate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OS(O)(=O)=O)=C1O XDBMXUKHMOFBPJ-ZAFYKAAXSA-N 0.000 description 1
- KIENGQUGHPTFGC-JLAZNSOCSA-N L-ascorbic acid 6-phosphate Chemical compound OP(=O)(O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O KIENGQUGHPTFGC-JLAZNSOCSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- AOMUHOFOVNGZAN-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)dodecanamide Chemical compound CCCCCCCCCCCC(=O)N(CCO)CCO AOMUHOFOVNGZAN-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010044625 Trichorrhexis Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- POXJXWXPDYFTJM-ZAFYKAAXSA-N [(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-yl] dihydrogen phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1OP(O)(O)=O POXJXWXPDYFTJM-ZAFYKAAXSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000003788 bath preparation Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- REZZEXDLIUJMMS-UHFFFAOYSA-M dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 description 1
- 239000004664 distearyldimethylammonium chloride (DHTDMAC) Substances 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 108060002894 fibrillar collagen Proteins 0.000 description 1
- 102000013373 fibrillar collagen Human genes 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000003719 hair strength Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 210000000301 hemidesmosome Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 102000007236 involucrin Human genes 0.000 description 1
- 108010033564 involucrin Proteins 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940031957 lauric acid diethanolamide Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
(1)L−アスコルビン酸、又はL−アスコルビン酸誘導体を含有することを特徴とするくせ毛改善剤。
(2)L−アスコルビン酸、又はL−アスコルビン酸誘導体を含有することを特徴とする毛包外構造改善剤。
(3)L−アスコルビン酸、又はL−アスコルビン酸誘導体を含有することを特徴とするタイプ14コラーゲン産生促進剤。
以下に、L−アスコルビン酸誘導体を用いた処方例を示す。
処方 含有量(重量%)
1.エタノール 60.0
2.L−アスコルビン酸2−グルコシド(株式会社林原) 2.0
3.グリセリン 2.0
4.精製水にて全量を100とする
[製造方法]成分2を成分4に溶解し、成分1及び成分3を加え、十分攪拌混合して製品とする。
処方例1において、L−アスコルビン酸2−グルコシド(株式会社林原)を精製水に置き換えたものを、従来のヘアトニックとする。
処方 含有量(重量%)
1.L−アスコルビン酸2−グルコシド(株式会社林原) 0.2
2.ステアリン酸 5.0
3.セチルアルコール 5.0
4.流動パラフィン 2.0
5.グリセリンモノステアレート 1.3
6.ソルビタンモノオレート 1.5
7.ポリオキシエチレンソルビタンモノオレエート(10E.O.) 0.8
8.グリセリン 6.0
9.防腐剤 適量
10.精製水にて全量を100とする
[製造方法]成分2〜7を加熱溶解して混合し、70℃に保ち油相とした。成分1および8〜10を加熱溶解して混合し、75℃に保ち水相とした。油相に水相を加え、かき混ぜながら冷却して製品とする。
処方 含有量(重量%)
1.L−アスコルビン酸2−グルコシド(株式会社林原) 0.1
2.アルキル硫酸トリエタノールアミン 18.0
3.ラウリン酸ジエタノールアミド 3.0
4.メチルセルロース 0.5
5.香料 適量
6.精製水にて全量を100とする
[製造方法]成分6に成分4を均一に溶解した後、成分1及び2を加え、70〜75℃で加熱溶解した後、成分3を加え、冷却途中に成分5を加え30℃まで冷却し製品とする。
処方 含有量(重量%)
1.L−アスコルビン酸2−グルコシド(株式会社林原) 0.1
2.ホホバ油 0.01
3.ベヘニルアルコール 3.0
4.1,3‐ブチレングリコール 5.0
5.塩化ジステアリルジメチルアンモニウム(75%) 8.0
6.クエン酸 0.05
7.香料 適量
8.精製水にて全量を100とする
[製造方法]成分1〜8を60℃で溶解し、撹拌して30℃まで冷却し製品とする。
処方 含有量(重量%)
1.L−アスコルビン酸2−グルコシド(株式会社林原) 0.1
2.カルボキシビニルポリマー 1.0
3.ヒドロキシエチルセルロース 0.5
4.1,3−ブチレングリコール 5.0
5.水酸化カリウム 0.5
6.95エタノール 5.0
7.エデト酸三ナトリウム 0.02
8.メチルパラベン 0.2
9.香料 適量
10.精製水にて全量を100とする
[製造方法]成分1〜4及び6〜10を均一混合した後、成分5を添加して製品とする。
処方 含有量(重量%)
1.L−アスコルビン酸2−グルコシド(株式会社林原) 0.5
2.スクワラン 5.0
3.オリーブ油 5.0
4.ホホバ油 5.0
5.セタノール 1.5
6.モノステアリン酸グリセリン 2.0
7.ポリオキシエチレンセチルエーテル(20E.O.) 3.0
8.ポリオキシエチレンソルビタンモノオレエート(20E.O.) 2.0
9.香料 適量
10.グリセリン 2.0
11.パラオキシ安息香酸メチル 0.2
12.プロピレングリコール 1.0
13.精製水にて全量を100とする
[製造方法]成分2〜8を加熱溶解して混合し、70℃に保ち油相とする。成分1及び10〜13を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化し、かき混ぜながら冷却し、45℃で成分9を加え、30℃まで冷却して製品とする。
処方 含有量(重量%)
1.L−アスコルビン酸2−グルコシド(株式会社林原) 1.0
2.乾燥コーンスターチ 25.0
3.カルボキシメチルセルロースカルシウム 24.0
4.微結晶セルロース 40.0
5.ポリビニルピロリドン 7.0
6.タルク 3.0
[製造方法]成分1〜5を混合し、次いで10%の水を結合剤として加えて、押出し造粒後乾燥する。成形した顆粒に成分6を加えて混合し打錠する。1錠0.52gとする。
処方 含有量(重量%)
1.L−アスコルビン酸2−グルコシド(株式会社林原) 5.0
2.微結晶セルロース 60.0
3.トウモロコシデンプン 15.0
4.乳糖 18.0
5.ポリビニルピロリドン 2.0
[製造方法]成分1〜5を混合して顆粒化した後、2号硬カプセルに250mg充填してカプセル剤とする。
処方 含有量(重量%)
1.L−アスコルビン酸2−グルコシド(株式会社林原) 5.0
2.微結晶セルロース 40.0
3.トウモロコシデンプン 55.0
[製造方法]成分1〜3を混合し、常法により散剤を得る。
ヒト由来線維芽細胞NB1RGBを用いて、L−アスコルビン酸誘導体によるタイプ14コラーゲンの産生促進効果を下記の条件にて測定した。
Forward GATCAGTGGCGCGTCAAGT(配列番号1)
Reverse GCTGGGAATCTGGTTGAGGAT(配列番号2)
GAPDH用のプライマーセット
Forward TGCACCACCAACTGCTTAGC(配列番号3)
Reverse TCTTCTGGGTGGCAGTGATG(配列番号4)
女性被験者を対象にL−アスコルビン酸誘導体含有頭皮外用剤による毛包外構造改善効果を下記の条件で測定した。
健常女性被験者12名(平均年齢38.8歳)を対象に、処方例1、又は比較例1に示すヘアトニックを1ヶ月間連用させた。連用前と連用1ヶ月後に、頭頂部の毛髪について、毛包開口部付近をマイクロスコープ(キーエンス、VHX−500)で観察し、さらに連用1ヶ月後にアンケートを行い、くせ毛の改善について調査した。
Claims (3)
- L−アスコルビン酸、又はL−アスコルビン酸誘導体を含有することを特徴とするくせ毛改善剤。
- L−アスコルビン酸、又はL−アスコルビン酸誘導体を含有することを特徴とする毛包外構造改善剤。
- L−アスコルビン酸、又はL−アスコルビン酸誘導体を含有することを特徴とするタイプ14コラーゲン産生促進剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017112250A JP2018203681A (ja) | 2017-06-07 | 2017-06-07 | くせ毛改善剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017112250A JP2018203681A (ja) | 2017-06-07 | 2017-06-07 | くせ毛改善剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2018203681A true JP2018203681A (ja) | 2018-12-27 |
Family
ID=64956390
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017112250A Pending JP2018203681A (ja) | 2017-06-07 | 2017-06-07 | くせ毛改善剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2018203681A (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110882173A (zh) * | 2019-12-05 | 2020-03-17 | 西北农林科技大学 | 一种靶向毛囊干细胞防治脱发的外用型日化品配方 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04182415A (ja) * | 1990-11-19 | 1992-06-30 | Kaminomoto Honpo:Kk | 発毛・養毛促進剤 |
JP2002212037A (ja) * | 2001-01-15 | 2002-07-31 | Showa Denko Kk | ヘア保護剤 |
US20030099605A1 (en) * | 2001-11-02 | 2003-05-29 | Browning Paul T. | Hair clarifying treatment |
JP2003171290A (ja) * | 2001-09-27 | 2003-06-17 | Hayashibara Biochem Lab Inc | コラーゲン産生増強剤の製造方法とその用途 |
WO2007086327A1 (ja) * | 2006-01-24 | 2007-08-02 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | 毛乳頭細胞増殖促進剤 |
JP2008526955A (ja) * | 2005-01-13 | 2008-07-24 | トリコジーン インク. | ビタミンc及びその誘導体を含む脱毛治療剤組成物 |
KR20110056884A (ko) * | 2009-11-23 | 2011-05-31 | 영남대학교 산학협력단 | 마그네슘 아스코르빌 포스페이트(map) 및 메틸설포닐메탄(msm) 혼합물을 유효성분으로 함유하는 탈모 방지 및 발모 개선용 조성물 |
JP2013537895A (ja) * | 2010-09-24 | 2013-10-07 | ユニリーバー・ナームローゼ・ベンノートシヤープ | 髪を直毛化する方法 |
US20160008248A1 (en) * | 2013-03-01 | 2016-01-14 | Revlon Consumer Products Corporation | Glycyrrhetinimidyl hydroxyproline alkyl esters and protected derivatives thereof |
-
2017
- 2017-06-07 JP JP2017112250A patent/JP2018203681A/ja active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04182415A (ja) * | 1990-11-19 | 1992-06-30 | Kaminomoto Honpo:Kk | 発毛・養毛促進剤 |
JP2002212037A (ja) * | 2001-01-15 | 2002-07-31 | Showa Denko Kk | ヘア保護剤 |
JP2003171290A (ja) * | 2001-09-27 | 2003-06-17 | Hayashibara Biochem Lab Inc | コラーゲン産生増強剤の製造方法とその用途 |
US20030099605A1 (en) * | 2001-11-02 | 2003-05-29 | Browning Paul T. | Hair clarifying treatment |
JP2008526955A (ja) * | 2005-01-13 | 2008-07-24 | トリコジーン インク. | ビタミンc及びその誘導体を含む脱毛治療剤組成物 |
WO2007086327A1 (ja) * | 2006-01-24 | 2007-08-02 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | 毛乳頭細胞増殖促進剤 |
KR20110056884A (ko) * | 2009-11-23 | 2011-05-31 | 영남대학교 산학협력단 | 마그네슘 아스코르빌 포스페이트(map) 및 메틸설포닐메탄(msm) 혼합물을 유효성분으로 함유하는 탈모 방지 및 발모 개선용 조성물 |
JP2013537895A (ja) * | 2010-09-24 | 2013-10-07 | ユニリーバー・ナームローゼ・ベンノートシヤープ | 髪を直毛化する方法 |
US20160008248A1 (en) * | 2013-03-01 | 2016-01-14 | Revlon Consumer Products Corporation | Glycyrrhetinimidyl hydroxyproline alkyl esters and protected derivatives thereof |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110882173A (zh) * | 2019-12-05 | 2020-03-17 | 西北农林科技大学 | 一种靶向毛囊干细胞防治脱发的外用型日化品配方 |
CN110882173B (zh) * | 2019-12-05 | 2022-06-17 | 西北农林科技大学 | 一种靶向毛囊干细胞防治脱发的外用型日化品配方 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1893911B (zh) | 含有四肽和三肽混合物的配方 | |
JP4229842B2 (ja) | L−アルギニンオリゴマーを含む化粧品処方 | |
EP1638991B1 (fr) | Composition cosmetique ou dermopharmaceutique pour reduire les signes du vieillissement cutane | |
JP3556167B2 (ja) | 抗グリケーション剤としての3,3’,5,5’−テトラヒドロキシスチルベンの使用 | |
JP2006117700A (ja) | 抗グリケーション剤としての少なくとも1つのスノキ属植物の抽出物の使用 | |
JP5866279B2 (ja) | 脱毛防止又は育毛促進のための組成物 | |
JP2006316050A (ja) | 抗シワ剤 | |
JP2008088075A (ja) | プロフィラグリン/フィラグリン産生促進剤、表皮角化細胞増殖促進剤、表皮/角層正常化用皮膚外用剤、プロフィラグリン及び/又はフィラグリン産生促進方法、及び表皮角化細胞増殖促進方法 | |
JP2014122183A (ja) | Dna損傷抑制剤 | |
JP2018203681A (ja) | くせ毛改善剤 | |
JP2019523300A (ja) | スキンケア製品およびその使用 | |
EP2533756B1 (fr) | Composition pour cheveux crepus et/ou tres secs | |
JP2010006844A (ja) | インスリン様成長因子−1分泌促進剤 | |
JP5166116B2 (ja) | 育毛剤 | |
JP5216414B2 (ja) | 育毛剤 | |
JP2003327523A (ja) | 皮膚外用剤 | |
KR102014102B1 (ko) | 메스키트 꿀을 포함하는 피부미용 개선용 조성물 | |
EP3888625A1 (en) | Composition for scalp and hair | |
EP3494955B1 (en) | Cosmetic composition for promoting hair growth | |
JP6957228B2 (ja) | 美容方法 | |
JP2023161047A (ja) | 育毛促進用組成物 | |
JP7236755B2 (ja) | 育毛用組成物、遺伝子の発現促進用組成物 | |
CN113058026B (zh) | Kisspeptin-234在促进毛发生长中的应用 | |
KR102633917B1 (ko) | 피부 탄력 강화용 조성물 | |
JP2021178777A (ja) | 化粧料又は皮膚外用剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200409 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210226 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210330 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210520 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211019 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211210 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220426 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220617 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20221011 |